Diabetic Retinopathy Market Value to grasp $2.49 billion by 2022, at CAGR of 14.4% | AMR
Pune, Maharashtra, India, September 14 2020 (Wiredrelease) Allied Analytics –:UPDATE AVAILABLE ON-DEMAND
According to the research report published by Allied Market Research, the global diabetic retinopathy market is expected to register a CAGR of 14.4% from 2016 to 2022. The research includes changing market dynamics, top impacting factors, key investment pockets, value chain, and competitive scenario. Through tabular and graphical representation, the report offers key insights on different aspects of the market such as current market size and estimations, region-wise analysis, and opportunities. Porter’s Five Forces analysis has been mentioned in the report to outline competitive intensity. The report is a helpful source of information to unlock potential from emerging countries and expand businesses to gain international presence. The proliferative diabetic retinopathy segment accounted for more than half of the total market in 2015.
Diabetic retinopathy (DR) is a medical condition of the eye prevalent in diabetic individuals. It is mainly caused due to damage of the blood vessels of the retina. Without timely treatment, the disease leads to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population. From 1990 to 2010, DR holds the fifth position among the most common causes of preventable blindness and severe visual impairment.
To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/2010
The market is expected to witness significant growth during the forecast period due to factors such as increase in prevalence of diabetes, growth in geriatric population, rise in incidence of blindness due to diabetes, and augment in focus on awareness, which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs can pose as a major obstacle for the growth of the diabetic retinopathy market. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are anticipated to provide several opportunities for the market growth.
Proliferative diabetic retinopathy segment accounted for a major market share (more than half) in 2015 as the disease is one of the leading causes of blindness in diabetic patients. Moreover, nearly 20% of the people suffering from diabetic retinopathy (any type) have proliferative diabetic retinopathy.
North America accounted for majority of the share (nearly two-fifths) in the market in 2015, and is expected to remain dominant throughout the forecast period. This is attributed to the increase in incidence of diabetes along with the rise in geriatric population, increased patient awareness about diabetic retinopathy, and favorable reimbursement framework for retinopathy procedures. In addition, presence of highly sophisticated healthcare infrastructure is anticipated to provide new growth opportunities for the key players in this market.
Inquire Before Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2010
The major companies profiled Are:
Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche, Novartis International AG, Pfizer, Regeneron Pharmaceuticals Inc., and Valeant Pharmaceutical.
The Other key players Are:
Boehringer Ingelheim GmbH, KOWA Company, Ltd., BCN Peptides S.A., and ThromboGenics NV.
Key Findings of the Diabetic Retinopathy Market
• Based on treatment type, laser surgeries segment accounted for more than two-fifths of the total market in 2015.
• Anti-VEGF drugs accounted for more than one-third of the total market in 2015.
• Diabetic macular edema segment is expected to grow at a high CAGR of 14.6% from 2016-2022
• Asia-Pacific is expected grow at a high CAGR of 15.4%, owing to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of diabetic retinopathy.
Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at email@example.com.